{"analyses":[{"ciLowerLimit":"0.12","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.57","groupDescription":"PP-CSF use in the high risk FN group was compared between the usual care (UC) group (Arm 2) and the intervention group (Arm 3 and 4 combined).","groupIds":["OG001","OG002","OG003"],"nonInferiorityType":"SUPERIORITY","pValue":"0.21","paramType":"Odds Ratio (OR)","paramValue":"0.44","statisticalComment":"Adjusted for age group, comorbidity, race, and Hispanic ethnicity.","statisticalMethod":"Regression, Logistic"},{"ciLowerLimit":"0.44","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"3.20","groupDescription":"PP-CSF use in the low risk FN group was compared between the usual care (UC) group (Arm 2) and the intervention group (Arm 3 and 4 combined).","groupIds":["OG001","OG002","OG003"],"nonInferiorityType":"SUPERIORITY","pValue":"0.74","paramType":"Odds Ratio (OR)","paramValue":"1.18","statisticalComment":"Adjusted for age, sex, and cancer type.","statisticalMethod":"Regression, Logistic"},{"ciLowerLimit":"0.70","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"7.08","groupDescription":"PP-CSF use in the intermediate risk FN group was compared between the usual care (UC) group (Arm 2) and the SOE for PP-CSF intervention group (Arm 3).","groupIds":["OG001","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"0.17","paramType":"Odds Ratio (OR)","paramValue":"2.23","statisticalComment":"Adjusted for age, sex, and cancer type.","statisticalMethod":"Regression, Logistic"},{"ciLowerLimit":"0.11","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.19","groupDescription":"PP-CSF use in the intermediate risk FN group was compared between the usual care (UC) group (Arm 2) and the alert against PP-CSF intervention group (Arm 4).","groupIds":["OG001","OG003"],"nonInferiorityType":"SUPERIORITY","pValue":"0.094","paramType":"Odds Ratio (OR)","paramValue":"0.36","statisticalComment":"Adjusted for age, sex, and cancer type.","statisticalMethod":"Regression, Logistic"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.3"},{"groupId":"OG001","value":"5.5"},{"groupId":"OG002","value":"7.2"},{"groupId":"OG003","value":"5.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"121"},{"groupId":"OG001","value":"128"},{"groupId":"OG002","value":"249"},{"groupId":"OG003","value":"208"}],"units":"Participants"}],"title":"Low Risk Group"},{"categories":[{"measurements":[{"groupId":"OG000","value":"37.1"},{"groupId":"OG001","value":"18.8"},{"groupId":"OG002","value":"37.1"},{"groupId":"OG003","value":"9.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"202"},{"groupId":"OG001","value":"207"},{"groupId":"OG002","value":"542"},{"groupId":"OG003","value":"304"}],"units":"Participants"}],"title":"Intermediate Risk Group"},{"categories":[{"measurements":[{"groupId":"OG000","value":"93.0"},{"groupId":"OG001","value":"95.8"},{"groupId":"OG002","value":"91.8"},{"groupId":"OG003","value":"86.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"384"},{"groupId":"OG001","value":"309"},{"groupId":"OG002","value":"490"},{"groupId":"OG003","value":"460"}],"units":"Participants"}],"title":"High Risk Group"},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.5"},{"groupId":"OG001","value":"53.1"},{"groupId":"OG002","value":"52.2"},{"groupId":"OG003","value":"45.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"707"},{"groupId":"OG001","value":"644"},{"groupId":"OG002","value":"1281"},{"groupId":"OG003","value":"972"}],"units":"Participants"}],"title":"All FN Risk Groups"}],"denoms":[{"counts":[{"groupId":"OG000","value":"707"},{"groupId":"OG001","value":"644"},{"groupId":"OG002","value":"1281"},{"groupId":"OG003","value":"972"}],"units":"Participants"}],"description":"To compare the use of primary prophylactic colony stimulating factor (PP-CSF) according to recommended clinical practice guidelines among participants registered at intervention components versus usual care components. Primary prophylaxis of CSF (PP-CSF) is defined as the initiation of granulocyte CSFs during the first cycle of myelosuppressive systemic therapy, given 24 to 72 hours after cessation of systemic therapy. Separate mixed effects logistic models will be fit to assess the effect of the intervention on PP-CSF use. The rate of CSF prescribing is defined as the percent of participants prescribed CSF as primary prophylaxis out of the total number of participants within each arm.","groups":[{"description":"CSF prescribing for patients taking anti-cancer drugs is based on existing automated system recommendations: CSF is recommended for drugs with high risk of FN; CSF is not recommended for drugs with low risk of FN.","id":"OG000","title":"Active Comparator: Clinic Group 1 (Clinics With Existing Automated System for CSF Prescribing)"},{"description":"CSF prescribing for patients taking anti-cancer drugs is based on existing clinical practice guidelines.","id":"OG001","title":"Active Comparator: Clinic Group 2 (Clinics With no Automated System for CSF Prescribing)"},{"description":"CSF prescribing for patients taking anti-cancer drugs is based on automated system recommendations: CSF is recommended for drugs with intermediate or high risk of FN; CSF is not recommended for drugs with low risk of FN.","id":"OG002","title":"Experimental: Clinic Group 3 (Clinics With Automated System for CSF Prescribing)"},{"description":"CSF prescribing for patients taking anti-cancer drugs is based on automated system recommendations: CSF is recommended for drug with high risk of FN; CSF is not recommended for drugs with intermediate or low risk of FN.","id":"OG003","title":"Experimental: Clinic Group 4 (Clinics With Automated System for CSF Prescribing)"}],"paramType":"NUMBER","populationDescription":"There was one participant in Arm 4, that was deemed as having an unavailable outcome and was excluded from this analysis population. Leaving Arm 4 with 972 analyzable participants rather than 973.","reportingStatus":"POSTED","timeFrame":"Baseline to up to 14 days","title":"Percentage of Participants With CSF Prescribed as Primary Prophylaxis","type":"PRIMARY","unitOfMeasure":"percentage of participants"}